Statistics for Regulus Therapeutics (id:6001 RGLS)

Valuation metrics

Market cap

91.70M

Enterprise value

5.64M

Trailing P/E (ttm)

-0.93

Forward P/E

-1.16

PEG ratio

-1.16

Price/Sales (ttm)

Price/Book (mrq)

1.06

Enterprise Value/Revenue

Enterprise Value/EBITDA

-0.13

Overview

Shares outstanding

65.50M

Float

42.41M

Shares short

1.69M

% Held by insiders

0.02%

% Held by institutions

0.88%

Average volume (10 days)

335.93K

Average volume (90 days)

Price summary

52-Week low

1.08

52-Week high

3.79

52-Week change

8.84%

Beta

1.63

50-Day moving average

1.54

200-Day moving average

1.88

Dividends and splits

Forward annual dividend rate

Forward annual dividend yield

Trailing annual dividend rate

0.00%

Trailing annual dividend yield

0.00

5-Year annual dividend yield

Payout ratio

0.00

Dividend date

October 04th, 2018

Ex-dividend date

Last split factor

2:1

Last split date

June 29th, 2022

Financials

Fiscal year

Fiscal year ends

December 31th, 2023

Most recent quarter (mrq)

September 30th, 2024

Profitability

Profit margin

0.00%

Operating margin

0.00%

Operational effectiveness

Return on assets

-42.39%

Return on equity

-72.36%

Income statement

Revenue (ttm)

0.00

Revenue per share (ttm)

0.00

Quarterly revenue growth (yoy)

Gross profit (ttm)

0.00

EBITDA

-44,258,000.00

Net income to common (ttm)

-41,628,000.00

Diluted EPS (ttm)

-1.02

Quarterly earnings growth (yoy)

Balance sheet

Total cash (mrq)

87.31M

Total cash per share (mrq)

1.33

Total debt (mrq)

1.24M

Total Debt/Equity (mrq)

1.43

Current ratio (mrq)

1.41K%

Book value per share (mrq)

1.32

Cash flow

Cash flow statement

-35,953,000.00

Levered free cash flow (LFCF)

-21,584,124.00